Close Menu

Cellular Research

10x will pay Becton Dickinson $25 million over four years and the firms have agreed to refrain from engaging in a legal battle on other fronts.

In response to BD's patent suit, 10x alleged BD's single-cell products infringe its own patents. 10x also asked the judge to dismiss BD's lawsuit.

The lawsuit comes a few days after a jury awarded Bio-Rad Laboratories $23.9 million in damages in a patent infringement suit against 10x Genomics.

In an AGBT presentation, one early-access user of BD's Resolve platform described how he used it to analyze gene expression from 1,200 kidney cells. 

The company launched the BD FACSseq flow cytometer and BD Precise Assays for high-throughput single-cell gene-expression analysis studies at the ASHG annual meeting.

BD plans to launch a cell sorter for the genomics market over the next six months and to release an automated NGS library prep system in early 2016.

BD plans to pair Cellular Research's highly multiplexed gene expression technology with its flow cytometry platforms.

The partners will jointly promote the BD FACS single-cell sorting instrument alongside Cellular Research's molecular bar-coding technology, Precise.

The approach combines barcoding of individual mRNA molecules from single cells with next-generation sequencing.

NEW YORK (GenomeWeb) — Cellular Research said today that it is collaborating with Seven Bridges Genomics to provide customers with a "complete analysis pipeline" to run RNA sequencing experiments.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.